St. Louis Trust Co Sells 649 Shares of Amgen Inc. (NASDAQ:AMGN)

St. Louis Trust Co reduced its position in shares of Amgen Inc. (NASDAQ:AMGN) by 14.6% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,784 shares of the medical research company’s stock after selling 649 shares during the period. St. Louis Trust Co’s holdings in Amgen were worth $1,219,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Capital Performance Advisors LLP bought a new position in Amgen during the third quarter valued at approximately $25,000. Hershey Financial Advisers LLC bought a new stake in Amgen in the second quarter worth $30,000. nVerses Capital LLC purchased a new position in shares of Amgen in the second quarter worth about $31,000. Bbjs Financial Advisors LLC bought a new stake in shares of Amgen in the 2nd quarter valued at about $33,000. Finally, Matrix Trust Co bought a new position in Amgen during the 3rd quarter worth approximately $36,000. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on AMGN. William Blair restated an “outperform” rating on shares of Amgen in a report on Tuesday, November 12th. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and issued a $305.00 price objective (down from $310.00) on shares of Amgen in a research report on Wednesday, August 7th. StockNews.com raised shares of Amgen from a “buy” rating to a “strong-buy” rating in a research report on Friday, November 1st. Wolfe Research started coverage on shares of Amgen in a research note on Friday. They set a “peer perform” rating on the stock. Finally, UBS Group lowered their price objective on shares of Amgen from $335.00 to $326.00 and set a “neutral” rating for the company in a report on Thursday, October 31st. One analyst has rated the stock with a sell rating, thirteen have issued a hold rating, eleven have assigned a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $333.57.

Amgen Stock Down 0.9 %

Shares of NASDAQ AMGN opened at $278.76 on Tuesday. The company has a market cap of $149.84 billion, a P/E ratio of 35.69, a PEG ratio of 2.53 and a beta of 0.60. The firm has a 50-day simple moving average of $319.90 and a two-hundred day simple moving average of $318.65. Amgen Inc. has a 1 year low of $260.52 and a 1 year high of $346.85. The company has a debt-to-equity ratio of 7.55, a current ratio of 1.32 and a quick ratio of 0.96.

Amgen (NASDAQ:AMGN) last released its earnings results on Wednesday, October 30th. The medical research company reported $5.58 earnings per share for the quarter, topping analysts’ consensus estimates of $5.11 by $0.47. The business had revenue of $8.50 billion for the quarter, compared to analyst estimates of $8.50 billion. Amgen had a return on equity of 168.35% and a net margin of 13.00%. The business’s revenue was up 23.2% compared to the same quarter last year. During the same quarter last year, the firm posted $4.96 earnings per share. Research analysts anticipate that Amgen Inc. will post 19.51 earnings per share for the current year.

Amgen Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, December 9th. Stockholders of record on Monday, November 18th will be given a dividend of $2.25 per share. This represents a $9.00 dividend on an annualized basis and a dividend yield of 3.23%. The ex-dividend date of this dividend is Monday, November 18th. Amgen’s dividend payout ratio (DPR) is presently 115.24%.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.